Literature DB >> 17894550

The N-terminal region of ABC50 interacts with eukaryotic initiation factor eIF2 and is a target for regulatory phosphorylation by CK2.

Sonia Paytubi1, Nicholas A Morrice, Jerome Boudeau, Christopher G Proud.   

Abstract

ABC50 is an ABC (ATP-binding cassette) protein which, unlike most ABC proteins, lacks membrane-spanning domains. ABC50 interacts with eIF2 (eukaryotic initiation factor 2), a protein that plays a key role in translation initiation and in its control, and in regulation of ribosomes. Here, we establish that the interaction of ABC50 with eIF2 involves features in the N-terminal domain of ABC50, the region of ABC50 that differs most markedly from other ABC proteins. This region also shows no apparent similarity to the eIF2-binding domains of other partners of eIF2. In contrast, the N-terminus of ABC50 cannot bind to ribosomes by itself, but it can in conjunction with one of the nucleotide-binding domains. We demonstrate that ABC50 is a phosphoprotein and is phosphorylated at two sites by CK2. These sites, Ser-109 and Ser-140, lie in the N-terminal part of ABC50 but are not required for the binding of ABC50 to eIF2. Expression of a mutant of ABC50 in which both sites are mutated to alanine markedly decreased the association of eIF2 with 80S ribosomal and polysomal fractions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17894550     DOI: 10.1042/BJ20070811

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  18 in total

1.  Identification of novel host cell binding partners of Oas1b, the protein conferring resistance to flavivirus-induced disease in mice.

Authors:  S C Courtney; H Di; B M Stockman; H Liu; S V Scherbik; M A Brinton
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

2.  Radiation protection following nuclear power accidents: a survey of putative mechanisms involved in the radioprotective actions of taurine during and after radiation exposure.

Authors:  Olav Albert Christophersen
Journal:  Microb Ecol Health Dis       Date:  2012-02-01

3.  Proteomic profiling identified multiple short-lived members of the central proteome as the direct targets of the addicted oncogenes in cancer cells.

Authors:  Tonggang Qi; Wei Zhang; Yun Luan; Feng Kong; Dawei Xu; Guanghui Cheng; Yunshan Wang
Journal:  Mol Cell Proteomics       Date:  2013-10-08       Impact factor: 5.911

4.  hABCF3, a TPD52L2 interacting partner, enhances the proliferation of human liver cancer cell lines in vitro.

Authors:  Juan Zhou; Ying Lin; Huili Shi; Keke Huo; Yanhong Li
Journal:  Mol Biol Rep       Date:  2013-09-20       Impact factor: 2.316

5.  Biochemical characterization of the mouse ABCF3 protein, a partner of the flavivirus-resistance protein OAS1B.

Authors:  Elizabeth Peterson; Emma Shippee; Margo A Brinton; Parjit Kaur
Journal:  J Biol Chem       Date:  2019-08-14       Impact factor: 5.157

6.  ABC50 promotes translation initiation in mammalian cells.

Authors:  Sonia Paytubi; Xuemin Wang; Yun W Lam; Luis Izquierdo; Mairi J Hunter; Eric Jan; Harinder S Hundal; Christopher G Proud
Journal:  J Biol Chem       Date:  2009-07-01       Impact factor: 5.157

Review 7.  m6A-mediated translation regulation.

Authors:  Kate D Meyer
Journal:  Biochim Biophys Acta Gene Regul Mech       Date:  2018-10-17       Impact factor: 4.490

8.  m6A Facilitates eIF4F-Independent mRNA Translation.

Authors:  Ryan A Coots; Xiao-Min Liu; Yuanhui Mao; Leiming Dong; Jun Zhou; Ji Wan; Xingqian Zhang; Shu-Bing Qian
Journal:  Mol Cell       Date:  2017-10-26       Impact factor: 17.970

Review 9.  ABC-F translation factors: from antibiotic resistance to immune response.

Authors:  Corentin R Fostier; Laura Monlezun; Farès Ousalem; Shikha Singh; John F Hunt; Grégory Boël
Journal:  FEBS Lett       Date:  2020-12-04       Impact factor: 4.124

Review 10.  Cystic fibrosis as a bowel cancer syndrome and the potential role of CK2.

Authors:  Anil Mehta
Journal:  Mol Cell Biochem       Date:  2008-07-05       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.